Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant)
Defines Aetna's medical necessity and experimental/investigational determinations for non-myeloablative (reduced intensity) allogeneic hematopoietic cell transplantation, lists covered and not-covered ICD-10/CPT/HCPCS/J-codes when selection criteria are met, and provides clinical background and evidence references. This is Part 1 of 2; criteria are those present in this part only.
Last review recorded 02/20/2024 with no clinical policy statement changes indicated in this part of the document.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.